HC Wainwright Issues Pessimistic Forecast for HRMY Earnings

Posted by on May 22nd, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) – Stock analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of Harmony Biosciences in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.97 per share for the quarter, down from their previous estimate of $1.09. HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $3.34 per share. HC Wainwright also issued estimates for Harmony Biosciences’ Q2 2027 earnings at $1.06 EPS, Q3 2027 earnings at $1.25 EPS, Q4 2027 earnings at $1.48 EPS, FY2027 earnings at $4.69 EPS and FY2030 earnings at $7.11 EPS.

Harmony Biosciences (NASDAQ:HRMY – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.21). The firm had revenue of $215.39 million during the quarter, compared to analyst estimates of $220.84 million. Harmony Biosciences had a net margin of 16.20% and a return on equity of 17.19%. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.78 earnings per share.

Other research analysts have also issued research reports about the company. Truist Financial upped their price objective on Harmony Biosciences from $25.00 to $29.00 and gave the stock a “hold” rating in a report on Friday, May 8th. Weiss Ratings lowered Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Deutsche Bank Aktiengesellschaft lowered Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 price objective on the stock. in a report on Monday, February 23rd. Finally, UBS Group dropped their price objective on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $40.89.

Read Our Latest Stock Report on Harmony Biosciences

Harmony Biosciences Stock Performance

Shares of HRMY opened at $30.49 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.56 and a current ratio of 3.58. The stock has a market capitalization of $1.77 billion, a P/E ratio of 12.29, a P/E/G ratio of 0.21 and a beta of 0.97. The company’s fifty day moving average is $29.40 and its two-hundred day moving average is $33.18. Harmony Biosciences has a 1 year low of $25.52 and a 1 year high of $40.87.

Institutional Trading of Harmony Biosciences

A number of institutional investors have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. boosted its position in Harmony Biosciences by 0.6% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company’s stock worth $1,762,000 after purchasing an additional 298 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Harmony Biosciences by 1.2% during the third quarter. Thrivent Financial for Lutherans now owns 28,639 shares of the company’s stock worth $789,000 after purchasing an additional 348 shares in the last quarter. Nebula Research & Development LLC boosted its position in Harmony Biosciences by 2.0% during the second quarter. Nebula Research & Development LLC now owns 17,403 shares of the company’s stock worth $550,000 after purchasing an additional 348 shares in the last quarter. Amalgamated Bank boosted its position in Harmony Biosciences by 3.8% during the third quarter. Amalgamated Bank now owns 11,328 shares of the company’s stock worth $312,000 after purchasing an additional 417 shares in the last quarter. Finally, Profund Advisors LLC boosted its position in Harmony Biosciences by 5.1% during the third quarter. Profund Advisors LLC now owns 10,803 shares of the company’s stock worth $298,000 after purchasing an additional 520 shares in the last quarter. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Harmony Biosciences Company Profile

(Get Free Report)

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.

Featured Articles

Earnings History and Estimates for Harmony Biosciences (NASDAQ:HRMY)

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.